Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24334718 | 0.95 | FOLH1 (0.91) | FOLH1 | |
| SCHEMBL24334480 | 0.95 | FOLH1 (0.91) | FOLH1 | |
| Vipivotide Tetraxetan SCHEMBL22313039 | 0.94 | FOLH1 (1.00) | FOLH1 | |
| Vipivotide Tetraxetan SCHEMBL21881849 | 0.94 | FOLH1 (1.00) | FOLH1 | |
| Vipivotide Tetraxetan SCHEMBL21872782 | 0.94 | FOLH1 (1.00) | FOLH1 | |
| Vipivotide Tetraxetan SCHEMBL24612683 | 0.94 | FOLH1 (1.00) | FOLH1 | |
| Vipivotide Tetraxetan SCHEMBL24729006 | 0.94 | FOLH1 (1.00) | FOLH1 | |
| Vipivotide Tetraxetan SCHEMBL24729005 | 0.94 | FOLH1 (1.00) | FOLH1 | |
| Vipivotide Tetraxetan SCHEMBL21316439 | 0.94 | FOLH1 (1.00) | FOLH1 | |
| Vipivotide Tetraxetan SCHEMBL21501570 | 0.94 | FOLH1 (1.00) | FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210283279-A1 | USE OF LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER | NOVARTIS AG (CH) | 2021-09-16 | — | — | US | disclosed |
| US-11045564-B2 | Labeled inhibitors of prostate specific membrane antigen (PSMA) as agents for the treatment of prostate cancer | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2021-06-29 | — | — | US | disclosed |
| US-10980901-B2 | Treatment of PMSA expressing cancers | THE EUROPEAN ATOMIC ENERGY COMMUNITY (EURATOM), REPRESENTED BY THE EUROPEAN COMMISSION (BE) | 2021-04-20 | — | — | US | disclosed |
| US-10471160-B2 | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2019-11-12 | — | — | US | disclosed |
| US-10398791-B2 | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2019-09-03 | — | — | US | disclosed |
| US-20160228587-A1 | LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PROSTATE CANCER | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2016-08-11 | — | — | US | disclosed |
| WO-2015055318-A1 | LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PROSTATE CANCER | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2015-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10471160-B2 | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer | KLK3, FOLH1, PSMA1 | FOLH1 2/4885 |
| US-20160228587-A1 | LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PROSTATE CANCER | KLK3, FOLH1, PSMA1 | FOLH1 2/4885 |
| US-11045564-B2 | Labeled inhibitors of prostate specific membrane antigen (PSMA) as agents for the treatment of prostate cancer | KLK3, FOLH1, PSMA1 | FOLH1 2/4885 |
| US-10980901-B2 | Treatment of PMSA expressing cancers | PMS2, GNRHR, MC5R | FOLH1 4/4885 |
| US-10398791-B2 | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer | KLK3, FOLH1, PSMA1 | FOLH1 2/4885 |
| US-20210283279-A1 | USE OF LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER | KLK3, FOLH1, PSMA1 | FOLH1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.